The big any-day-now biotech news we’re keeping an eye on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the latest biotech startup to downsize, a novel idea in cancer treatment, and a few major catalysts on the calendar.

The need-to-know this morning

• Kyverna Therapeutics, a biotech developing CAR-T treatments for autoimmune diseases, filed for an initial public offering. Its lead product, called KYV-101, is a patient-specific, CD19-targeted cell therapy for lupus nephritis, currently in a mid-stage clinical trial.

A buzzy biotech cuts staff, acknowledges setbacks

Dewpoint Therapeutics, a biotech startup that has raised nearly $300 million, has laid off 15% of its staff and acknowledged a pair of high-profile partnerships fell apart.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In